Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alimta To Replace Taxotere As Standard For Non-Small Cell Lung Cancer – Lilly

This article was originally published in The Pink Sheet Daily

Executive Summary

Lilly expects its non-small cell lung cancer therapy Alimta (pemetrexed) to replace Taxotere (docetaxel) as the standard of care in the second-line setting, Exec VP-Pharmaceutical Operations John Lechleiter said Jan. 11 at the J.P. Morgan health care conference in San Francisco

You may also be interested in...



Lilly’s Alimta Brochure Does Not Include Specific Indication, Says DDMAC

The firm pulled the patient brochure after receiving an untitled letter from FDA’s ad division.

Lilly’s Alimta Brochure Does Not Include Specific Indication, Says DDMAC

The firm pulled the patient brochure after receiving an untitled letter from FDA’s ad division.

Iressa Promotion Halted; AstraZeneca To Highlight Tarceva Survival Benefit

Gefitinib fails to demonstrate a survival benefit in the Iressa Survival Evaluation in Lung cancer confirmatory trial. AstraZeneca will meet with FDA to determine whether accelerated approval licensure of Iressa will be withdrawn, CEO McKillop says.

Related Content

Topics

UsernamePublicRestriction

Register

PS060845

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel